BMS Entered into a Collaboration with GentiBio for the Development of New Treg Therapies Against Inflammatory Bowel Diseases
Shots:
- GentiBio to receive undisclosed upfront cash & is eligible to receive ~$1.9B in development & commercial milestones along with royalties. The collaboration will combine GentiBio’s Treg platform with BMS’ cell therapies & immunology leadership
- Through the extended partnership, the Treg platform will be applied to produce stable & disease-specific engineered Tregs against multiple targets whereas BMS will receive the right to develop & advance 3 of the resulting programs into clinical trials for IBD patients
- GentiBio’s Treg platform is a T cell platform that generates highly selective & durable Tregs with the potential to suppress inflammation & autoimmune dysfunction
Ref: PR Newswire | Image: BMS
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
